Key takeaways:

Earlier initiation of donanemab reduced the risk of disease progression on the Clinical Dementia Rating-Global Score.

More than 75% of patients treated with donanemab attained amyloid clearance within 76 weeks.

Treatment with IV donanemab in early-stage Alzheimer’s disease demonstrated sustained clinical benefits for up to 3 years, with early initiation responsible for better outcomes, data from a long-term extension study show.

“The long-term extension of TRAILBLAZER-ALZ 2 helped address the need for long-term data on the durability of treatment and established safety profile of Kisunla (donamemab, Eli Lilly & Co.) over time,” Mark A. Mintun, MD, group vice president, Neuroscience Research and Development, Eli Lilly and Co., told Healio regarding the research, which w

See Full Page